摘要
目的探讨新辅助化疗联合手术与单纯手术治疗食管癌的临床疗效。方法将2013年9月至2014年9月胸外科符合入选标准的受试者100例作为研究对象。将所有患者按照随机分配原则分为对照组和试验组,对照组患者行单纯手术治疗,试验组患者行新辅助化疗联合手术治疗。比较两组患者的生存率、生活质量改善情况以及术后复发情况。结果试验组患者在生存率、生活质量改善以及术后复发情况均优于对照组,差异均有统计学意义(均P<0.05)。结论对于食管癌患者,新辅助化疗联合手术治疗的临床治疗效果比单纯手术治疗效果更好。
Objective To explore the clinical curative effect of new adjuvant chemotherapy combined with operation and simple operation in the treatment of esophageal carcinoma.Methods Selected 100 patients who met inclusioncriteria from 2013 September to 2014 September department of thoracic surgery as the research object.All patients were divided into control group and test group according to the random distribution, patients in the control group received simple operation,the test group were treated with new adjuvant chemotherapy combined with operation. Compared the survival rate of the patients,the improvement of the quality of life, postoperative recurrence of two groups.Results The patients in the survival rate,improve the life quality and postoperative recurrence were superior to the control group,the difference was statistically significant(P〈0.05). Conclusion For patients with esophageal cancer, the clinical therapeutic effect of new adjuvant chemotherapy combined with operation is better than simple operative.
出处
《中国药物经济学》
2015年第6期79-81,共3页
China Journal of Pharmaceutical Economics
关键词
新辅助化疗
食管癌
手术治疗
New adjuvant chemotherapy
Esophageal cancer
Surgical treatment